ORBIMED ADVISORS LLC
13F Reported Value
ⓘ$5.4B
incl. option notional
Equity Holdings
ⓘ$5.3B
Option Notional
ⓘ$117.4M
$48.8M puts / $68.5M calls
Holdings
129
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
ORBIMED ADVISORS LLC disclosed 129 positions worth $5.4B in its Form 13F-HR for Q2 2026 — $5.3B in common stock plus $117.4M of put/call option positions (reported at underlying notional value, not premium at risk), led by $EWTX (Edgewise Therapeutics, Inc.) at 11.9% of the equity portfolio, followed by $ELVN and $LLY. During the quarter the fund opened 40 new positions and exited 24 — including a new stake in $UNH and a full exit from $MDXH. The portfolio is most concentrated in Healthcare (98.0% of disclosed assets). All figures are sourced directly from ORBIMED ADVISORS LLC’s Form 13F-HR filing with the SEC under CIK 1055951.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$630.5M15,518,492 sh - —
Quality
$343.9M6,776,632 sh - 87.5#2
Quality
$309.3M257,900 sh - —
Quality
$189.3M3,428,736 sh - —
Quality
$184.5M2,718,735 sh - —
Quality
$171.1M915,700 sh - —
Quality
$118.6M2,209,400 sh - —
Quality
$112.4M2,555,877 sh - —
Quality
$107.0M7,165,006 sh - —
Quality
$105.2M3,027,328 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Edgewise Therapeutics, Inc.$EWTX | — | $630.5M | 15,518,492 |
 Enliven Therapeutics, Inc.$ELVN | — | $343.9M | 6,776,632 |
 ELI LILLY & Co$LLY | 87.5#2 | $309.3M | 257,900 |
 MBX Biosciences, Inc.$MBX | — | $189.3M | 3,428,736 |
 SINOVAC BIOTECH LTD$SVA | — | $184.5M | 2,718,735 |
 ASTRAZENECA PLC$AZN | — | $171.1M | 915,700 |
 Structure Therapeutics Inc.$GPCR | — | $118.6M | 2,209,400 |
 Sionna Therapeutics, Inc.$SION | — | $112.4M | 2,555,877 |
 Corvus Pharmaceuticals, Inc.$CRVS | — | $107.0M | 7,165,006 |
 ArriVent BioPharma, Inc.$AVBP | — | $105.2M | 3,027,328 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of ORBIMED ADVISORS LLC's 129 positions.
Showing top 10 of 129 holdings.
Sector Allocation
Healthcare
$5.2B
Technology
$75.9M
Energy
$30.3M
Other
$1.1M
Full Holdings — ORBIMED ADVISORS LLC (Q2 2026)
All 129 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $EWTX | Edgewise Therapeutics, Inc. | $630.5M | 11.9% | +0% | — |
| 2 | $ELVN | Enliven Therapeutics, Inc. | $343.9M | 6.5% | -15% | — |
| 3 | $LLY | ELI LILLY & Co | $309.3M | 5.9% | +9% | 87.5 |
| 4 | $MBX | MBX Biosciences, Inc. | $189.3M | 3.6% | -6% | — |
| 5 | $SVA | SINOVAC BIOTECH LTD | $184.5M | 3.5% | +0% | — |
| 6 | $AZN | ASTRAZENECA PLC | $171.1M | 3.2% | +37% | — |
| 7 | $GPCR | Structure Therapeutics Inc. | $118.6M | 2.3% | +50% | — |
| 8 | $SION | Sionna Therapeutics, Inc. | $112.4M | 2.1% | -28% | — |
| 9 | $CRVS | Corvus Pharmaceuticals, Inc. | $107.0M | 2.0% | +0% | — |
| 10 | $AVBP | ArriVent BioPharma, Inc. | $105.2M | 2.0% | +0% | — |
| 11 |  $GH | Guardant Health, Inc. | $87.6M | 1.7% | +34% | 39 |
| 12 |  $ARGX | ARGENX SE | $86.2M | 1.6% | -32% | — |
| 13 |  $MRK | Merck & Co., Inc. | $85.2M | 1.6% | +0% | 59.9 |
| 14 |  $QURE | uniQure N.V. | $83.3M | 1.6% | -15% | — |
| 15 |  $PRAX | Praxis Precision Medicines, Inc. | $77.0M | 1.5% | +33% | — |
| 16 |  $EW | Edwards Lifesciences Corp | $75.5M | 1.4% | -32% | 69.4 |
| 17 |  $PRLD | Prelude Therapeutics Inc | $73.2M | 1.4% | +26% | 21.5 |
| 18 |  $ABVX | Abivax S.A. | $72.8M | 1.4% | +17% | — |
| 19 |  $DYN | Dyne Therapeutics, Inc. | $71.9M | 1.4% | +11% | — |
| 20 |  $NTRA | Natera, Inc. | $71.1M | 1.4% | +0% | 53.5 |
| 21 |  $CGON | CG Oncology, Inc. | $69.1M | 1.3% | +3% | 27 |
| 22 |  $UNH | UNITEDHEALTH GROUP INC | $67.0M | 1.3% | NEW | 62.7 |
| 23 |  $SPRY | ARS Pharmaceuticals, Inc. | $66.4M | 1.3% | +0% | 20.3 |
| 24 |  $ASND | Ascendis Pharma A/S | $65.2M | 1.2% | +34% | 44.8 |
| 25 |  $HUM | HUMANA INC | $65.2M | 1.2% | NEW | 58.9 |
| 26 |  $COGT | Cogent Biosciences, Inc. | $65.1M | 1.2% | +422% | — |
| 27 |  $BSX | BOSTON SCIENTIFIC CORP | $63.3M | 1.2% | -38% | 77.5 |
| 28 |  $ISRG | INTUITIVE SURGICAL INC | $62.8M | 1.2% | -24% | 79.9 |
| 29 |  $MLYS | Mineralys Therapeutics, Inc. | $56.9M | 1.1% | +3% | — |
| 30 |  $ODTX | Odyssey Therapeutics, Inc. | $56.2M | 1.1% | NEW | — |
| 31 |  $XENE | Xenon Pharmaceuticals Inc. | $53.9M | 1.0% | -16% | 24 |
| 32 |  $ARQT | Arcutis Biotherapeutics, Inc. | $53.5M | 1.0% | NEW | 62.9 |
| 33 |  $BMY | BRISTOL MYERS SQUIBB CO | $53.3M | 1.0% | +0% | 70.4 |
| 34 |  $FIXX | Q32 Bio Inc. | $52.6M | 1.0% | +83% | 36.4 |
| 35 |  $SYK | STRYKER CORP | $50.1M | 0.9% | -13% | 72.1 |
| 36 |  $CAI | Caris Life Sciences, Inc. | $50.0M | 0.9% | +0% | 69 |
| 37 | — | SPDR SERIES TRUST - ST STR SP BIOT | $47.5M | — | NEW | — |
| 38 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $45.5M | 0.9% | +95% | 65.1 |
| 39 |  $PVLA | PALVELLA THERAPEUTICS, INC. | $44.7M | 0.8% | +117% | — |
| 40 |  $ELV | Elevance Health, Inc. | $44.4M | 0.8% | +0% | 59 |
| 41 |  $STTK | Shattuck Labs, Inc. | $43.8M | 0.8% | +0% | — |
| 42 |  $UPB | Upstream Bio, Inc. | $39.4M | 0.8% | +0% | 19.7 |
| 43 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $37.4M | 0.7% | +0% | 25.5 |
| 44 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $35.9M | 0.7% | +3% | 33.9 |
| 45 |  $SNDX | Syndax Pharmaceuticals Inc | $33.7M | 0.6% | +60% | 33.8 |
| 46 |  $FBRX | Forte Biosciences, Inc. | $33.5M | 0.6% | +32% | — |
| 47 |  $CMPX | Compass Therapeutics, Inc. | $33.3M | 0.6% | +0% | 28.1 |
| 48 |  $NKTR | NEKTAR THERAPEUTICS | $32.5M | 0.6% | +69% | 9.7 |
| 49 |  $KRYS | Krystal Biotech, Inc. | $30.9M | 0.6% | +20% | 79.2 |
| 50 |  $NOV | NOV Inc. | $30.3M | 0.6% | -9% | 47.8 |
| 51 |  $AXSM | Axsome Therapeutics, Inc. | $28.8M | 0.6% | -45% | 40.8 |
| 52 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $26.9M | 0.5% | +133% | — |
| 53 |  $TRVI | Trevi Therapeutics, Inc. | $26.7M | 0.5% | -42% | — |
| 54 | $ABVXCALL | Abivax S.A. | $26.7M | — | NEW | — |
| 55 |  $IRON | Disc Medicine, Inc. | $26.2M | 0.5% | -67% | — |
| 56 |  $WST | WEST PHARMACEUTICAL SERVICES INC | $25.3M | 0.5% | NEW | 64.4 |
| 57 |  $RLMD | RELMADA THERAPEUTICS, INC. | $25.1M | 0.5% | -23% | — |
| 58 |  $URGN | UroGen Pharma Ltd. | $24.9M | 0.5% | -23% | — |
| 59 |  $STRO | SUTRO BIOPHARMA, INC. | $24.7M | 0.5% | -7% | 15.3 |
| 60 |  $SVRA | Savara Inc | $24.4M | 0.5% | +524% | — |
| 61 |  $NPCE | NeuroPace Inc | $23.9M | 0.5% | -28% | 32.4 |
| 62 |  $AURA | Aura Biosciences, Inc. | $23.7M | 0.5% | NEW | — |
| 63 |  $ORIC | Oric Pharmaceuticals, Inc. | $21.8M | 0.4% | -25% | — |
| 64 |  $HELP | CYBIN INC. | $21.6M | 0.4% | -15% | — |
| 65 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $18.5M | 0.3% | +30% | 53.2 |
| 66 |  $BIOA | BioAge Labs, Inc. | $18.4M | 0.3% | +6% | 26.8 |
| 67 |  $PTGXCALL | Protagonist Therapeutics, Inc | $18.4M | — | NEW | 59.4 |
| 68 |  $LXEO | Lexeo Therapeutics, Inc. | $18.4M | 0.3% | +10% | — |
| 69 |  $WHWK | Whitehawk Therapeutics, Inc. | $18.0M | 0.3% | -6% | 26.4 |
| 70 |  $DFTX | Definium Therapeutics, Inc. | $17.2M | 0.3% | -55% | — |
| 71 |  $SYRE | Spyre Therapeutics, Inc. | $16.5M | 0.3% | NEW | — |
| 72 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $16.3M | 0.3% | +0% | — |
| 73 |  $VERA | Vera Therapeutics, Inc. | $15.9M | 0.3% | +0% | — |
| 74 |  $ALMS | ALUMIS INC. | $15.4M | 0.3% | +0% | 7.1 |
| 75 |  $EYPT | EyePoint, Inc. | $15.3M | 0.3% | +0% | 3.5 |
| 76 |  $WAT | WATERS CORP /DE/ | $15.1M | 0.3% | NEW | 60.4 |
| 77 |  $MNPR | Monopar Therapeutics | $14.6M | 0.3% | NEW | — |
| 78 |  $TVTX | Travere Therapeutics, Inc. | $14.4M | 0.3% | NEW | 56.6 |
| 79 |  $TSHA | Taysha Gene Therapies, Inc. | $13.6M | 0.3% | NEW | 4.9 |
| 80 |  $BIIB | BIOGEN INC. | $13.3M | 0.3% | +0% | 64.7 |
| 81 |  $RVMD | Revolution Medicines, Inc. | $13.2M | 0.3% | +36% | — |
| 82 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $11.2M | 0.2% | NEW | 22.6 |
| 83 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $10.8M | 0.2% | NEW | — |
| 84 |  $LFST | LifeStance Health Group, Inc. | $10.1M | 0.2% | +89% | 63.4 |
| 85 | $RVMDCALL | Revolution Medicines, Inc. | $9.4M | — | NEW | — |
| 86 |  $ERAS | Erasca, Inc. | $9.1M | 0.2% | NEW | — |
| 87 |  $TARA | Protara Therapeutics, Inc. | $8.5M | 0.2% | NEW | — |
| 88 |  $KROS | Keros Therapeutics, Inc. | $8.1M | 0.1% | +0% | 27.3 |
| 89 |  $JANX | Janux Therapeutics, Inc. | $8.1M | 0.1% | -47% | 30.1 |
| 90 |  $TECX | Tectonic Therapeutic, Inc. | $7.8M | 0.1% | +0% | — |
| 91 |  $ACET | Adicet Bio, Inc. | $7.3M | 0.1% | -18% | — |
| 92 |  $PHVS | Pharvaris N.V. | $7.1M | 0.1% | +0% | — |
| 93 |  $ANRO | Alto Neuroscience, Inc. | $6.8M | 0.1% | +54% | — |
| 94 |  $ZNTL | Zentalis Pharmaceuticals, Inc. | $6.7M | 0.1% | NEW | 11.6 |
| 95 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $6.5M | 0.1% | +133% | — |
| 96 | $PVLACALL | PALVELLA THERAPEUTICS, INC. | $6.1M | — | -20% | — |
| 97 |  $ALXO | ALX ONCOLOGY HOLDINGS INC | $5.9M | 0.1% | +0% | — |
| 98 | $TVTX | Travere Therapeutics, Inc. | $5.9M | 0.1% | NEW | 56.6 |
| 99 |  $XLO | Xilio Therapeutics, Inc. | $5.7M | 0.1% | NEW | 35.6 |
| 100 |  $BCAX | Bicara Therapeutics Inc. | $5.7M | 0.1% | -71% | — |
| 101 |  $IMA | ImageneBio, Inc. | $5.4M | 0.1% | +140% | 6.6 |
| 102 | $PTGX | Protagonist Therapeutics, Inc | $5.2M | 0.1% | +0% | 59.4 |
| 103 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $5.1M | 0.1% | -86% | 71.4 |
| 104 |  $PALI | PALISADE BIO, INC. | $4.9M | 0.1% | +0% | — |
| 105 | $RVMD | Revolution Medicines, Inc. | $4.4M | 0.1% | NEW | — |
| 106 |  $ATAI.R1840904 | Atai Beckley N.V. | $4.2M | 0.1% | +130% | — |
| 107 | $UNHCALL | UNITEDHEALTH GROUP INC | $4.2M | — | NEW | 62.7 |
| 108 |  $PTCT | PTC THERAPEUTICS, INC. | $4.0M | 0.1% | +0% | 35.4 |
| 109 |  $AORT | ARTIVION, INC. | $3.9M | 0.1% | +16% | 48.1 |
| 110 | $ELVCALL | Elevance Health, Inc. | $3.9M | — | NEW | 59 |
| 111 |  $NMRA | Neumora Therapeutics, Inc. | $3.6M | 0.1% | NEW | — |
| 112 |  $ACAD | ACADIA PHARMACEUTICALS INC | $3.5M | 0.1% | NEW | 67.8 |
| 113 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $3.3M | 0.1% | NEW | 8.7 |
| 114 |  $TYRA | Tyra Biosciences, Inc. | $3.3M | 0.1% | NEW | — |
| 115 |  $RAPP | Rapport Therapeutics, Inc. | $3.2M | 0.1% | NEW | — |
| 116 |  $AGMB | Agomab Therapeutics NV | $2.5M | 0.1% | NEW | — |
| 117 |  $TARS | Tarsus Pharmaceuticals, Inc. | $2.2M | 0.0% | NEW | 55 |
| 118 |  $ACRS | Aclaris Therapeutics, Inc. | $2.2M | 0.0% | NEW | 12 |
| 119 |  $CYTK | CYTOKINETICS INC | $2.2M | 0.0% | NEW | 28.1 |
| 120 |  $NSPR | InspireMD, Inc. | $2.2M | 0.0% | +0% | — |
| 121 |  $OCUL | OCULAR THERAPEUTIX, INC | $2.2M | 0.0% | NEW | 8.4 |
| 122 |  $EVMN | Evommune, Inc. | $2.1M | 0.0% | NEW | 14.9 |
| 123 |  $BLTE | BELITE BIO, INC | $2.0M | 0.0% | NEW | — |
| 124 |  $OVID | Ovid Therapeutics Inc. | $2.0M | 0.0% | NEW | 26.4 |
| 125 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $1.8M | 0.0% | NEW | — |
| 126 |  $SLSPUT | SELLAS Life Sciences Group, Inc. | $1.4M | — | NEW | — |
| 127 | $COGT | Cogent Biosciences, Inc. | $1.2M | 0.0% | +0% | — |
| 128 | — | VIRIDIAN THERAPEUTICS INC - NOTE 1.750% 5/1 | $1.1M | 0.0% | NEW | — |
| 129 |  $TRAW | Traws Pharma, Inc. | $1.0M | 0.0% | +99% | — |
New Positions (40)
$UNH UNITEDHEALTH GROUP INC$67.0M$HUM HUMANA INC$65.2M$ODTX Odyssey Therapeutics, Inc.$56.2M$ARQT Arcutis Biotherapeutics, Inc.$53.5M$ABVXCALL Abivax S.A.$26.7M$WST WEST PHARMACEUTICAL SERVICES INC$25.3M$AURA Aura Biosciences, Inc.$23.7M$PTGXCALL Protagonist Therapeutics, Inc$18.4M$SYRE Spyre Therapeutics, Inc.$16.5M$WAT WATERS CORP /DE/$15.1M$MNPR Monopar Therapeutics$14.6M$TVTX Travere Therapeutics, Inc.$14.4M$TSHA Taysha Gene Therapies, Inc.$13.6M$DNTH Dianthus Therapeutics, Inc. /DE/$11.2MExited Positions (24)
$MDXHCALL MDxHealth SA
$RCELCALL AVITA Medical, Inc.
$MYGN MYRIAD GENETICS INC
$PFE PFIZER INC
$DHR DANAHER CORP /DE/$RCEL AVITA Medical, Inc.
$ESPR Esperion Therapeutics, Inc.
$BTSG BrightSpring Health Services, Inc.
$AMGN AMGEN INC
$ALHC Alignment Healthcare, Inc.
$REGN REGENERON PHARMACEUTICALS, INC.
$CARL CARLSMED, INC.
$QGENCALL QIAGEN N.V.
$GILD GILEAD SCIENCES, INC.
$HRTX HERON THERAPEUTICS, INC. /DE/Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for ORBIMED ADVISORS LLC including:
Track ORBIMED ADVISORS LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for ORBIMED ADVISORS LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: ORBIMED ADVISORS LLC
13F Pro is an AI hedge fund tracker and stock research platform. For ORBIMED ADVISORS LLC (SEC CIK: 1055951), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in ORBIMED ADVISORS LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.